Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

被引：2

作者：

Park, John W. ^{[1
]}

Liu, Minetta C. ^{[2
]}

Yee, Douglas ^{[3
]}

DeMichele, Angela ^{[4
]}

van't Veer, Laura ^{[1
]}

Hylton, Nola ^{[1
]}

Symmans, Fraser ^{[5
]}

Buxton, Meredith B. ^{[1
]}

Chien, A. Jo ^{[1
]}

Wallace, Amy ^{[6
]}

Melisko, Michelle ^{[1
]}

Schwab, Richard ^{[6
]}

Boughey, Judy ^{[2
]}

Tripathy, Debashish ^{[7
]}

Kaplan, Hank ^{[8
]}

Nanda, Rita ^{[9
]}

Chui, Stephen ^{[10
]}

Albain, Kathy S. ^{[11
]}

Moulder, Stacy ^{[5
]}

Elias, Anthony ^{[12
]}

Lang, Julie E. ^{[7
]}

Edminston, Kirsten ^{[13
]}

Northfelt, Donald ^{[14
]}

Euhus, David ^{[15
]}

Khan, Qamar ^{[16
]}

Lyandres, Julia ^{[1
]}

Davis, Sarah E. ^{[1
]}

Yau, Christina ^{[1
]}

Sanil, Ashish ^{[17
]}

Esserman, Laura J. ^{[1
]}

Berry, Donald A. ^{[17
]}

机构：

[1] UCSF, San Francisco, CA USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Minnesota, Minneapolis, MN USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Calif San Diego, San Diego, CA 92103 USA

[7] Univ So Calif, Los Angeles, CA USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Univ Chicago, Chicago, IL 60637 USA

[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[11] Loyola Univ, Chicago, IL 60611 USA

[12] Univ Denver, Denver, CO USA

[13] Inova Fairfax Hosp, Falls Church, VA USA

[14] Mayo Clin, Scottsdale, AZ USA

[15] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[16] Univ Kansas, Lawrence, KS 66045 USA

[17] Berry Consultants, Austin, TX USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-CT227

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT227

引用

页数：2

共 50 条

[1] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2013, 73
[2] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Albain, K. S.
Leyland-Jones, B.
Symmans, F.
Paoloni, M.
van't Veer, L.
DeMichele, A.
Buxton, M.
Hylton, N.
Yee, D.
Clennell, J. Lyandres
Yau, C.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2016, 76
[3] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Yau, Christina
Wolf, Denise M.
Sanil, Ashish
Chien, Jo
Wallace, Anne
Boughey, Judy
Yee, Doug
Tripathy, Debu
DeMichele, Angela
Nanda, Rita
Chiu, Steven
Isaacs, Claudine
Albain, Kathy
Kaplan, Hank
Moulder, Stacey
Viscusi, Rebecca
Northfelt, Donald
Edmiston, Kirsten
Elias, Anthony
Styblo, Toncred
Haley, Barbara
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian L.
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, W. Fraser
Esserman, Laura
Berry, Don
Liu, Minetta C.
Park, John W.
van 't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[5] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[6] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[7] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Wang, Haiyun
Yee, Douglas
[J]. CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 303 - 310
[8] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Haiyun Wang
Douglas Yee
[J]. Current Breast Cancer Reports, 2019, 11 : 303 - 310
[9] Efficacy of pertuzumab/trastuzumab /paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Buxton, Meredith
DeMichele, Angela M.
Chia, Stephen
van't Veer, Laura
Chien, Jo
Wallace, Anne
Kaplan, Henry
Lang, Julie
Yee, Douglas
Isaacs, Claudine
Moulder, Stacy
Albain, Kathy
Boughey, Judy
Kemmer, Kathleen
Haley, Barbara
Minton, Susan
Forero, Andres
Nanda, Rita
Elias, Anthony
Korde, Larissa
Viscuzi, Rebecca
Rugo, Hope
Schwab, Richard
Symmans, Fraser
Paoloni, Melissa
Hylton, Nola
Hogarth, Michael
Lyandres, Julia
Perlmutter, Jane
Sanil, Ashish
Yau, Christina
Esserman, Laura
Berry, Don
[J]. CANCER RESEARCH, 2016, 76
[10] Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer
Wolf, Denise M.
Yau, Christina
Brown-Swigart, Lamorna
O'Grady, Nick
Hirst, Gillian
Sit, Laura
Asare, Smita
Berry, Don
Esserman, Laura
Han, Hyo
Pusztai, Lajos
van 't Veer, Laura
[J]. CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →